LLY
Eli Lilly and CompanyThesis. LLY is the definitional GLP-1 growth story — Mounjaro/Zepbound driving +55% YoY revenue and a 4-for-4 beat streak averaging +19% EPS surprise. At 27.8x forward and 31.5x EV/EBITDA the stock is priced for perfection and sits at an all-time high, but consistent upside revisions (JPM to $1,400) and a 50% EBITDA margin justify accumulating on weakness rather than chasing strength.
Scoreboard
LLY trades at $1,235.56, printing a fresh 52-week high ($1,249.45) and sitting in the 98th percentile of its $623.78–$1,249.45 range — a near-100% advance off the low. Market cap is $1.10T against a $1.14T enterprise value. Consensus mean target of $1,228.25 is fractionally below spot (-0.59%), but that number is stale; the $1,265.50 median and $1,500 high, alongside JPM's fresh $1,400 raise, point to positive revision momentum the mean has not yet caught.
QoQ Changes
Q1 2026 revenue hit $19.80B, up 2.6% QoQ from $19.29B and part of a relentless sequential climb from $15.56B in Q2 2025. Basic EPS of $8.28 rose 11.6% QoQ from $7.42 and blew past the $6.73 Street estimate by 27%.
Gross margin held elite at ~82%, with Q1 gross profit of $16.22B on $19.80B revenue. Operating income of $9.78B implies a ~49% operating margin, up from $8.99B prior quarter, though reported EBITDA of $10.29B stepped down from an unusually high $12.14B in Q4 2025.
FCF margin is a modest 12.7% and FCF yield just 0.83%, reflecting heavy capacity capex to feed incretin demand. Cash generation lags reported earnings as Lilly pours capital into manufacturing build-outs — a quality caveat on an otherwise pristine P&L.
Total cash of $5.28B ($5.92/share) is dwarfed by $43.37B of debt, leaving a net debt position of $38.09B. Debt/equity of 139% looks heavy but is comfortably serviced given 50% EBITDA margins; current ratio of 1.50 and quick ratio of 0.72 are adequate.
At 42.5x trailing and 27.8x forward earnings, 15.3x sales and 31.5x EV/EBITDA, LLY commands a premium to every large-cap pharma peer. PEG of 1.55 is the only multiple that looks reasonable, and only because forward growth is exceptional.
Lilly handed Chinese partner Innovent full commercial control of Verzenio, sharpening focus on the incretin core, and the market cap re-rated higher as IPO rival Kailera posted weak weight-loss pill data — reinforcing LLY's pipeline lead. Orforglipron (oral GLP-1, licensed via Chugai) remains the strategic swing factor.
Ownership & Insider Activity
Institutions own 85.3% and short interest is negligible at 1.09% of float (2.99 days to cover), leaving no meaningful bear positioning. Finnhub Form 4 data shows net insider selling of $18.6M with zero purchases — dominated by Lilly Endowment's routine open-market sales ($15.75M across two 5/6 tranches) and officer Ilya Yuffa's $2.88M sale at $1,150.77 on 6/10. Director activity was purely comp-driven (code 'A' grants), so the selling reads as diversification and tax management, not a governance signal.
Recent Insider Transactions
| Date | Insider | Position | Shares | Value |
|---|---|---|---|---|
| 2026-06-15 | SULZBERGER GABRIELLE | Director | 4 | $5.0K |
| 2026-06-15 | ALVAREZ RALPH | Director | 10 | $12.4K |
| 2026-06-15 | FYRWALD J. ERIK | Director | 8 | $9.9K |
| 2026-06-15 | LUCIANO JUAN R | Director | 14 | $15.9K |
| 2026-06-10 | YUFFA ILYA | Officer | 2,500 | $2.9M |
| 2026-05-18 | SULZBERGER GABRIELLE | Director | 5 | $5.0K |
Earnings Quality
| Period | Actual EPS | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
| 2026-03-31 Q1 | $8.55 | $6.73 | +$1.82 | +27.04% |
| 2025-12-31 Q4 | $7.54 | $6.74 | +$0.80 | +11.92% |
| 2025-09-30 Q3 | $7.02 | $5.75 | +$1.27 | +22.05% |
| 2025-06-30 Q2 | $6.31 | $5.51 | +$0.80 | +14.50% |
LLY beat consensus in 4 of the last 4 quarters with an average surprise of +18.9% — a durable execution premium that signals both real demand and conservative Street modeling.
Surprises are widening, not fading: +14.5% (Q2'25) → +22.0% → +11.9% → +27.0% (Q1'26), evidence that analysts remain structurally miscalibrated to the pace of incretin uptake.
Analyst Action
| Month | Distribution | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|---|
| 2026-07 | 11 | 19 | 7 | 1 | 0 | |
| 2026-06 | 11 | 20 | 7 | 1 | 0 | |
| 2026-05 | 11 | 19 | 8 | 1 | 0 | |
| 2026-04 | 12 | 18 | 8 | 1 | 0 |
The rating panel is stable and bullish — 11 Strong Buy / 19 Buy / 7 Hold / 1 Sell in July, essentially unchanged from 12/18/8/1 in April, with Buys marginally firming. JPMorgan's Chris Schott raised his target to $1,400 from $1,300 in early July, reiterating Overweight.
Momentum is quietly bullish: no downgrades in the visible window and price targets drifting up faster than the consensus mean can refresh.
Seven Essential Metrics
EBITDA margin ~50%, operating margin 49.4%, and an extraordinary ROE of 107% on 20.7% ROA.
Revenue +55.5% YoY and earnings +169.9%, among the fastest in mega-cap pharma.
FCF margin of only 12.7% and 0.83% FCF yield lag earnings as capex funds incretin capacity.
Net debt of $38.1B and debt/equity of 139%, but easily covered by 50% EBITDA margins.
Beta of 0.51, 85% institutional ownership, and negligible short interest; primary risk is valuation, not solvency.
27.8x forward P/E, 31.5x EV/EBITDA, and 15.3x sales — a full premium to every pharma peer.
Growth is reinvested into capacity and pipeline; dividend is token and buybacks modest versus capex intensity.
A dividend-growth name in profile but yield is immaterial; this is a total-return, capital-appreciation story.
Competitive Snapshot
| Company | EBITDA Margin | 3Y Rev CAGR | FCF Margin | Leverage | Fwd P/E |
|---|---|---|---|---|---|
NVO Novo Nordisk | ~48% | ~25% | ~30% | Net cash | ~18x |
MRK Merck & Co. | ~42% | ~7% | ~22% | <1x | ~11x |
ABBV AbbVie | ~50% | ~3% | ~30% | ~3x | ~15x |
PFE Pfizer | ~35% | -10% | ~18% | ~2x | ~9x |
LLY carries roughly double the forward multiple of the pharma complex, but it is the only name in the cohort growing revenue at 55% with a 50% EBITDA margin. Novo Nordisk is the sole true GLP-1 comparable and trades far cheaper (~18x) after execution stumbles, framing the pair trade; the legacy trio (MRK, ABBV, PFE) offer value and yield but structurally slower growth. The premium is earned on growth, though it leaves zero margin for a pipeline or reimbursement misstep.
Business & Strategy
Cardiometabolic health is the engine — Mounjaro (T2D) and Zepbound (obesity) are the incretin blockbusters, layered on the legacy insulin franchise (Humalog, Humulin, Basaglar) and Jardiance. Oncology (Verzenio, Jaypirca, Retevmo), immunology (Taltz, Omvoh, Ebglyss), and Alzheimer's (Kisunla) diversify but are secondary to the GLP-1 flywheel.
Sales flow through payers, PBMs, hospital systems, and pharmacies across the US, Europe, China, and Japan, with US commercial and Medicare the dominant channel.
Predominantly patented small-molecule and biologic drug sales, supplemented by collaboration and licensing economics (Boehringer on Jardiance, Chugai on orforglipron, Almirall on Ebglyss).
Manufacturing capacity expansion for incretins, heavy R&D, and SG&A/marketing intensity are the core cost lines, with capex currently suppressing free cash conversion.
Lilly's moat is a manufacturing and pipeline lead in incretins that rivals cannot replicate on a short horizon, protected by patents, trial data, and multi-year capacity scale-up. Orforglipron, an oral GLP-1, could extend the moat into a far larger addressable market than injectables alone.
Monetary-Policy Sensitivity
- Long-duration growth equity — lower discount rate lifts terminal value
- Low beta (0.51) dampens beta-driven upside
- Defensive healthcare demand largely rate-insensitive at the fundamental level
As a long-duration, high-multiple compounder, LLY's valuation benefits mechanically from a lower discount rate, but its 0.51 beta and defensive cash flows mute the magnitude versus higher-beta growth names. Rates are a second-order driver here; drug demand and pipeline execution dominate the equation.
SWOT Analysis
- Incretin franchise (Mounjaro/Zepbound) driving +55% revenue growth
- 50% EBITDA margin and 107% ROE — elite profitability
- 4-for-4 earnings beats averaging +19% surprise
- Manufacturing and pipeline lead rivals cannot quickly close
- FCF margin of only 12.7% and 0.83% FCF yield lag reported earnings
- Net debt of $38.1B, debt/equity 139%
- Revenue concentration in the incretin category
- Token dividend yield offers no downside cushion
- Orforglipron oral GLP-1 unlocking a far larger addressable market
- Obesity TAM expansion into cardiovascular, sleep apnea, MASH indications
- Alzheimer's (Kisunla) and next-gen oncology optionality
- International/China scale-up as capacity comes online
- Valuation priced for perfection — 27.8x forward, 31.5x EV/EBITDA
- Competitive incretin pipelines (Novo, Amgen, others) and compounding/pricing pressure
- US drug-pricing policy and Medicare negotiation risk
- Manufacturing bottlenecks or a clinical readout miss
Catalysts & Event Risks
- Q3 2026Q2 2026 earnings
Next print tests whether the +19% average surprise streak and incretin momentum extend into 2H.
- 2H 2026Orforglipron regulatory/data progression
Oral GLP-1 milestones are the largest single catalyst for re-rating the addressable market.
- Q3 2026Zepbound label/indication expansion
New obesity-adjacent indications (sleep apnea, cardiovascular) widen the reimbursable base.
- 2H 2026Competitor readouts
Rival weight-loss pill failures (e.g., Kailera) continue to accrue value to LLY's lead.
- Q4 20262027 guidance
Management's capacity and revenue framing will set the durability-of-growth debate for next year.
The binary swing factor is orforglipron — an oral GLP-1 that could re-rate the TAM and justify the current multiple, or disappoint and puncture it. Near term, another double-digit EPS beat and label expansions are the base-case supports.
Technical Analysis
LLY is in a clean, powerful uptrend, printing a fresh 52-week high at $1,249.45 and sitting in the 98th percentile of its annual range. Price is well above the 50-day ($1,066.85) and 200-day ($989.57) moving averages, with the 50-day the first line of support and the 52-week high the immediate resistance. The setup is momentum-positive but extended — risk-reward favors accumulating on a pullback toward the $1,066 area rather than chasing at the highs. A break and hold above $1,250 opens a path toward the $1,400 JPM target.
Verdict
Macro context. Healthcare is drawing defensive flows amid an AI-led Nasdaq wobble, and with US healthcare spending topping $5.7T, structural demand tailwinds favor category leaders. The overhang is US drug-pricing policy and Medicare negotiation, which caps the sector's re-rating even as incretin demand stays supply-constrained.
Eli Lilly is the highest-quality growth franchise in pharma — 55% revenue growth, 50% EBITDA margins, a 4-for-4 beat streak, and a widening incretin lead that competitors cannot quickly erode. The counterweight is valuation: at an all-time high, 27.8x forward earnings and 31.5x EV/EBITDA, the stock discounts flawless execution and leaves scant room for a pipeline or policy misstep, while the consensus mean target already sits at spot. We rate LLY ACCUMULATE with a $1,320 target (~6.8% upside), preferring to add on pullbacks toward the 50-day rather than chase the high — the business deserves ownership, but entry discipline earns the returns.
Data source: Yahoo Finance / yfinance · fetched 7/8/2026, 6:41:41 AM